Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Mar 20, 2022 1:35pm
85 Views
Post# 34529639

RE:RE:RE:RE:Estimates ...

RE:RE:RE:RE:Estimates ...Most of the net income or losses have come mainly via swings in equity from investments. That doesn't really matter especially since the investments have achieved double digit returns over time which is the important part. Also, management has mentioned they will likely divest over time when the opportunities arise.

The more important aspect in terms of earnings is the company's cash flow which is more relavent. Cash flow is starting to snowball and this quarter should be a good one. Covid was still very present in Q4 and that boost to sales in Q3 could be seen in Q4 as well. Then there's Exelon transfer profits. I'm hopeful this will be above $70M in revenues again. 

Looks like the market agrees as they bid up leading to Q4 results. If the earnings are good this may finally break out of the range to the upside. 

<< Previous
Bullboard Posts
Next >>